Logo
x

Search

Subscribe Now

Lymphoma

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

TG Therapeutics' Ukoniq (umbralisib) Receives the US FDA's Approval for R/R Marginal Zone Lymphoma and Follicular Lymphoma

  • February 2, 2021
MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

MorphoSys' Monjuvi (tafasitamab-cxix) + Lenalidomide Receives the US FDA's Approval as 2L Treatment for Patients with Relapsed or...

  • August 3, 2020
Celltrion Report Results of Truxima (biosimilar- rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25

Celltrion Report Results of Truxima (biosimilar- rituximab) Based Regimen in P-II Study for R/R Aggressive B-cell Lymphoma #EHA25

  • June 16, 2020
Roche's Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC's Approval for Patients with R/R Diffuse Large B-Cell Lymphoma

Roche's Polivy (polatuzumab vedotin) Based Combination Regimen Receives EC's Approval for Patients with R/R Diffuse Large B-Cell L...

  • January 21, 2020
Roche's Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA's Accelerated Approval for Relapsed/Refractory Lymphoma

Roche's Polivy (polatuzumab vedotin-piiq) Combination Therapy Receives FDA's Accelerated Approval for Relapsed/Refractory Lymphoma

  • June 11, 2019
Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults

Bayer's Aliqopa (copanlisib) Receives the US FDA's Breakthrough Therapy Designation to Treat Marginal Zone Lymphoma in Adults

  • May 29, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.